{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:04:27Z","timestamp":1782302667202,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A 47-year-old woman with hypertension and rheumatoid arthritis presented with non-necrotizing scleritis in both eyes. Despite a course of oral corticosteroids, she continued to experience persistent symptoms. A rheumatologist was consulted and initiated treatment with tofacitinib, a JAK\/STAT inhibitor. Treatment with tofacitinib and oral corticosteroids resulted in an improvement in the scleritis in both eyes. However, a fundus examination of her left eye revealed a superior-temporal branch retinal vein occlusion. Given the growing concern regarding the increased risk of thromboembolic events with tofacitinib therapy, it is essential to consider the risk of retinal vascular occlusions when starting tofacitinib therapy, particularly in patients with underlying systemic comorbidities.<\/jats:p>","DOI":"10.1186\/s12348-023-00359-w","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T13:02:32Z","timestamp":1695819752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinib"],"prefix":"10.1186","volume":"13","author":[{"given":"Anitha","family":"Manoharan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshita","family":"Atmakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthopratim","family":"Dutta Majumder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotirmay","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"issue":"9","key":"359_CR1","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.4103\/ijo.IJO_534_20","volume":"68","author":"R Pyare","year":"2020","unstructured":"Pyare R, Kaushik V, Dutta Majumder P, Biswas J (2020) Tofacitinib in recalcitrant scleritis: first case report from India. Indian J Ophthalmol 68(9):1988\u20131990. https:\/\/doi.org\/10.4103\/ijo.IJO_534_20","journal-title":"Indian J Ophthalmol"},{"key":"359_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","volume":"13","author":"MA Paley","year":"2019","unstructured":"Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ (2019) Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 13:53\u201355. https:\/\/doi.org\/10.1016\/j.ajoc.2018.12.001","journal-title":"Am J Ophthalmol Case Rep"},{"key":"359_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2022.2113805","volume":"20","author":"R Pyare","year":"2022","unstructured":"Pyare R, Dutta Majumder P, Shah M, Kaushik V, Agarwal M, Biswas J (2022) Tofacitinib in Scleritis: a Case Series. Ocul Immunol Inflamm Published online September 20:1\u20137. https:\/\/doi.org\/10.1080\/09273948.2022.2113805","journal-title":"Ocul Immunol Inflamm Published online September"},{"issue":"18","key":"359_CR4","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","volume":"77","author":"S Dhillon","year":"2017","unstructured":"Dhillon S, Tofacitinib (2017) A review in rheumatoid arthritis. Drugs 77(18):1987\u20132001. https:\/\/doi.org\/10.1007\/s40265-017-0835-9","journal-title":"Drugs"},{"key":"359_CR5","unstructured":"Pfizer (2023) PHASE 3B\/4 Randomized safety endpoint study of 2 doses of tofacitinib in comparison to a tumor necrosis factor (TNF) INhibitor in subjects with rheumatoid arthritis. clinicaltrials.gov; 2021. Accessed April 3, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02092467"},{"issue":"4","key":"359_CR6","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 386(4):316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"359_CR7","unstructured":"Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase - PubMed. Accessed 5 April\u00a0 2023.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/32533433\/"},{"issue":"11","key":"359_CR8","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1007\/s10067-021-05911-4","volume":"40","author":"S Mori","year":"2021","unstructured":"Mori S, Ogata F, Tsunoda R (2021) Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol 40(11):4457\u20134471. https:\/\/doi.org\/10.1007\/s10067-021-05911-4","journal-title":"Clin Rheumatol"},{"issue":"9","key":"359_CR9","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jama.2013.1099","volume":"309","author":"KL Winthrop","year":"2013","unstructured":"Winthrop KL, Baddley JW, Chen L et al (2013) Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 309(9):887\u2013895. https:\/\/doi.org\/10.1001\/jama.2013.1099","journal-title":"JAMA"},{"issue":"10","key":"359_CR10","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL (2016) Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75(10):1843\u20131847. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209131","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"359_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","volume":"75","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Lee EB, Kaplan IV et al (2016) Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis 75(5):831\u2013841. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205847","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"359_CR12","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB et al (2014) Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 41(5):837\u2013852. https:\/\/doi.org\/10.3899\/jrheum.130683","journal-title":"J Rheumatol"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-023-00359-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-023-00359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T05:17:27Z","timestamp":1700371047000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-023-00359-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1186\/s12348-023-00359-w","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not relevant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"\u00a0Ethics approval and consent to participate"}},{"value":"This paper has never been submitted to any journal nor published in any form of media before. Authors provide consent for publication into the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"\u00a0Consent for publication"}},{"value":"\u00a0The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}